Gordon Sanghera was co-founder of Oxford Nanopore Technologies, together with Hagan Bayley and IP Group. He was appointed CEO in June 2005.
He has over 20 years’ experience in the design, development and global launch of disruptive platform sensor technologies. Dr Sanghera’s PhD in bioelectronics sensing was followed by a career at MediSense an Oxford spin-out that delivered a new generation glucose technology to the market.
Following the acquisition of MediSense by Abbott Laboratories Dr Sanghera held both UK and US VP and Director-level positions, including VP World Wide Marketing, Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose bio-electronic systems for the consumer and hospital medical markets. He has also developed and validated production processes to meet with the regulatory requirements for USA and Europe.
Gordon has a PhD in bio-electronic technology and a degree in Chemistry. To date, Oxford Nanopore has raised a total of £451m.